Last Updated: April 30, 2026

CLINICAL TRIALS PROFILE FOR ZORTRESS


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Zortress

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00419159 ↗ Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy Completed Novartis Pharmaceuticals Phase 2 2006-12-01 To assess the safety and efficacy of weekly (70 mg per week) and daily (10 mg per day) everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite prior treatment with targeted therapy and chemotherapy.
NCT00622869 ↗ Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients Completed Novartis Pharmaceuticals Phase 3 2008-01-01 This trial was designed to address important issues that impact recipients of liver allografts as well as clinicians, ie, renal function, reduction or discontinuation of tacrolimus early post-transplantation, and progression rate of fibrosis in hepatitis C virus (HCV) positive patients.
NCT00651482 ↗ Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) Terminated Genentech, Inc. Phase 2 2008-08-01 To determine the safety and efficacy of the combination of bevacizumab and everolimus (RAD001) for the treatment of metastatic renal cell cancer
NCT00651482 ↗ Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) Terminated Novartis Phase 2 2008-08-01 To determine the safety and efficacy of the combination of bevacizumab and everolimus (RAD001) for the treatment of metastatic renal cell cancer
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zortress

Condition Name

Condition Name for Zortress
Intervention Trials
Breast Cancer 4
Advanced Malignant Solid Neoplasm 3
Kidney Transplant 3
Metastatic Malignant Solid Neoplasm 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zortress
Intervention Trials
Neoplasms 13
Carcinoma 12
Carcinoma, Renal Cell 5
Renal Insufficiency 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zortress

Trials by Country

Trials by Country for Zortress
Location Trials
United States 319
Italy 13
Canada 13
Japan 12
Spain 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zortress
Location Trials
Texas 26
California 19
Ohio 16
Illinois 14
Colorado 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zortress

Clinical Trial Phase

Clinical Trial Phase for Zortress
Clinical Trial Phase Trials
Phase 4 8
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zortress
Clinical Trial Phase Trials
Completed 18
Recruiting 17
Terminated 11
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zortress

Sponsor Name

Sponsor Name for Zortress
Sponsor Trials
National Cancer Institute (NCI) 22
M.D. Anderson Cancer Center 16
Novartis Pharmaceuticals 14
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zortress
Sponsor Trials
Other 73
Industry 37
NIH 24
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Zortress Market Analysis and Financial Projection

Last updated: April 27, 2026

ZORTRESS (everolimus) Clinical Trials Update and Market Outlook

ZORTRESS is the brand of everolimus (mTOR inhibitor) marketed by Novartis for kidney transplant (stages vary by region) and subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC). The commercial profile is driven by (1) ongoing immunosuppressive uptake in transplant populations where everolimus-based regimens are used, (2) durable demand in TSC-associated SEGA treated with oral everolimus, and (3) competitive pressure from other mTOR or pathway-directed regimens in oncology subsets and from calcineurin-inhibitor optimization in transplant.


What is ZORTRESS’s current clinical footprint?

Core indications and development maturity

ZORTRESS has moved from development to standard-of-care positioning in its key labeled uses, with the clinical program centered on:

  • Kidney transplant maintenance regimens and exposure-optimization strategies (tacrolimus minimization and regimen adjustment).
  • TSC-associated SEGA treatment, typically aligned to an ongoing, repeatable oral dosing framework.

Clinical trials update: what is the direction of travel?

Across the labeled landscape, the trend is consistent with two objectives:

  • Transplant: use everolimus to reduce calcineurin inhibitor exposure while maintaining efficacy and improving tolerability profiles relevant to chronic outcomes.
  • TSC/SEGA: sustain tumor control with long-term oral dosing and manage safety monitoring over extended treatment duration.

Implication for R&D and investing: ZORTRESS’s clinical narrative is not “early pipeline expansion” but “optimization and durability.” That matters for revenue durability because it reduces the probability of abrupt label disruption and increases the value of new regimen combinations, adherence programs, and real-world dosing refinement.


Which trials matter for ZORTRESS right now?

Transplant program themes

Trial designs in this segment generally evaluate:

  • Everolimus with reduced-exposure tacrolimus versus standard exposure.
  • Maintenance timing and dose titration rules.
  • Safety endpoints tied to infections, metabolic events, and renal function trajectory.

TSC-associated SEGA themes

Trial designs in this segment generally evaluate:

  • Efficacy on SEGA response endpoints (objective radiographic control and duration).
  • Safety monitoring patterns in long-term therapy.
  • Dosing management for mucositis, infections, hematologic effects, and metabolic events.

Investment read-through: ZORTRESS’s most value-relevant clinical updates tend to be regimen-related and long-term safety clarity rather than breakthrough efficacy claims.


How is ZORTRESS performing in the market?

Category and demand drivers

ZORTRESS sits at the intersection of:

  • Transplant immunosuppression where clinicians trade off efficacy versus tolerability and long-horizon kidney function.
  • Neuro-oncology in TSC where oral mTOR inhibition is a defined disease-modifying pathway.

Demand drivers by geography

  • US: transplant immunosuppression is competitive and protocolized; usage depends on payer coverage, center protocols, and patient selection.
  • EU/UK: mTOR-based regimens remain a significant option; adoption is influenced by guideline penetration and reimbursement.
  • Emerging markets: uptake tracks access pathways and local payer coverage; barriers tend to be reimbursement and monitoring infrastructure.

What is the competitive landscape for everolimus in this space?

Competitive dynamics

Competition for ZORTRESS is not limited to other brand everolimus. It includes:

  • Other immunosuppressive strategies in transplant (tacrolimus optimization, other mTOR combinations, and alternative immunosuppressants).
  • Other oncology pathway therapies in TSC-adjacent spaces (though mTOR is central to SEGA management).

Pricing and substitution pressure

  • In transplant immunosuppression, substitution dynamics often hinge on guideline alignment and payer formularies.
  • In SEGA, substitution depends on clinical acceptability of equivalent dosing and tolerability experience.

Business takeaway: ZORTRESS’s pricing power is constrained where generic entry and payer substitution occur, while clinical protocol anchoring can protect use in certain cohorts.


What does the market projection look like?

Forecast framework (projection logic)

A practical projection for ZORTRESS typically models:

  1. Volume growth from treated population expansion and incremental share within transplant protocols.
  2. Dose persistence driven by long-term therapy duration.
  3. Price erosion from generic competition and payer contracting.
  4. Indication and reimbursement stability for SEGA.

Market projection direction

  • Transplant: likely flat-to-moderate growth in mature geographies, with fluctuations driven by formulary changes and protocol shifts.
  • TSC/SEGA: likely steady growth driven by persistent diagnosis-treated prevalence, though growth rate is capped by incidence and intensity of monitoring.

Net: a profile consistent with mature specialty revenue: low-to-mid single digit growth in peak markets is the typical pattern when price erosion offsets volume gains.


How do clinical trial developments affect forecast risk?

Risk factors that move revenue faster than label changes

  • Protocol shifts in transplant centers that move patients away from everolimus-based regimens.
  • Safety signal changes that impact clinician confidence in long-term maintenance use.
  • Payer pathway shifts (step therapy, prior authorization tightening, or substitution policies).
  • Competition and substitution pressures in any market where everolimus is broadly available.

Key upside levers

  • Better tolerated dosing paradigms and clearer long-term safety data.
  • Expanded payer coverage and improved patient flow for SEGA monitoring.
  • Center-level standardization of mTOR-based protocols.

What is the practical investment and R&D action list?

For R&D prioritization

  • Focus on regimen optimization rather than proof-of-concept, given maturity of the clinical narrative.
  • Invest in long-term real-world evidence (adherence, dosing stability, management of AEs) since that can drive protocol and payer confidence.
  • Target tolerability improvements through dosing algorithms and supportive care frameworks.

For investment decisioning

  • Treat the thesis as specialty franchise management rather than pipeline optionality.
  • Model revenue with a split of volume/persistence versus price erosion.
  • Discount aggressively for payer substitution and formulary erosion in markets with generic availability.

Key Takeaways

  • ZORTRESS’s market story is anchored in two established therapeutic pillars: transplant immunosuppression and TSC-associated SEGA.
  • The most decision-relevant clinical updates tend to be regimen optimization and long-term safety consistency, not new transformative efficacy endpoints.
  • Market outlook is consistent with a mature specialty profile where price erosion risk can offset volume growth, leaving flat-to-moderate growth as the base case.
  • Competitive dynamics are driven by protocol standardization in transplant and substitution/payer policies in both indications.

FAQs

1) Is ZORTRESS a pipeline or franchise bet?

ZORTRESS is primarily a franchise bet due to the clinical maturity in its labeled uses and the emphasis on optimizing and sustaining long-term use.

2) What drives transplant revenue for ZORTRESS?

It is driven by uptake of everolimus-based maintenance regimens, persistence under dosing protocols, and payer/formulary access that supports continued use.

3) What drives TSC/SEGA revenue for ZORTRESS?

It is driven by the treated SEGA population, long-term oral therapy persistence, and reimbursement stability for ongoing monitoring and dosing.

4) What is the main market risk to ZORTRESS?

Price erosion and substitution pressure under payer and generic dynamics, plus protocol shifts that reduce everolimus-based regimen use.

5) What type of clinical updates matter most?

Updates that clarify long-term safety, tolerability management, and regimen execution in real-world practice.


References

[1] Novartis. Zortress (everolimus) prescribing information.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.